The Medicines and Healthcare products Agency (MHRA) has authorised the use of a new drug for the treatment of locally advanced or metastatic HR-positive, HER 2-negative breast cancer.
Capivasertib (Truqap; AstraZeneca), an AKT inhibitor, works by blocking the effects of proteins called AKT…
[ad_2]
Source link
